More than 2 years since the approval of the natalizumab biosimilar (reference product, Tysabri), partners Sandoz and Polpharma Biologics have yet to introduce neurologists to the concept of biosimilar prescribing. The reason is a JC virus test submitted by the biosimilar manufacturers, which is required for patients prior to receiving natalizumab treatment, has not yet … Continue reading The Early Outlook for Ocrelizumab Biosimilars